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Introduction: Recent clinical success of epidermal growth factor
(EGFR)-tyrosine kinase inhibitors (TKIs) in non-small cell lung
cancer (NSCLC) have raised hopes that targeting other deregulated
growth factor signaling, such as the hepatocyte growth factor/MET
pathway, will lead to new therapeutic options for NSCLC. Further-
more, NSCLC present secondary EGFR-TKIs resistance related to
exons 20 and 19 EGFR mutations or more recently to MET ampli-
fication. The aim of this study was to determine MET copy number
related to EGFR copy number and K-Ras mutations in a targeted
TKI naive NSCLC cohort.
Methods: We investigated 106 frozen tumors from surgically re-
sected NSCLC patients. Genes copy number of MET and EGFR
were assessed by quantitative relative real-time polymerase chain
reaction and K-Ras mutations by sequencing.
Results: MET is amplified in 22 cases (21%) and deleted in nine cases
(8.5%). EGFR is amplified in 31 cases (29%). K-Ras is mutated in 11
cases (10.5%). As observed for EGFR amplification, MET amplifi-
cation is never associated with K-Ras mutation. MET amplification
could be associated with EGFR amplification. MET amplification is
not related to clinical and pathologic features. MET amplification
and EGFR amplification showed a trend toward poor prognosis in
adenocarcinomas.
Conclusion: In EGFR-TKIs naive NSCLC patients, MET amplifi-
cation is a frequent event, which could be associated with EGFR
amplification, but not with K-Ras mutation. MET amplification may
identify a subset of NSCLC for new targeted therapy. It will also be
important to evaluate MET copy number to properly interpret future
clinical trials.
Key Words: Non-small cell lung cancer, EGFR gene, MET gene,
K-Ras gene.
(J Thorac Oncol. 2008;3: 331–339)
Lung cancer is the leading cause of cancer in many devel-oped countries, including the United States and the Eu-
rope.1 Non-small cell lung cancers (NSCLCs) represent 80%
of lung cancers, further classified into adenocarcinoma
(ADC) including bronchioloalveolar carcinoma (BAC) and
squamous cell carcinoma (SCC). ADC have shown an in-
creasing incidence, particularly in females and nonsmokers.2
The tyrosine-kinase epidermal growth factor (EGFR) recep-
tor pathway has been shown to play a essential role in the
pathogenesis of NSCLC, leading to the development of
targeted therapeutic agents using small molecules EGFR-
tyrosine kinase inhibitors (TKIs) such as gefitinib or erlo-
tinib.3–6 In fact, only few patients could benefit from EGFR-
TKIs therapy, with dramatic response.
This recent clinical success of EGFR-TKIs in refrac-
tory, advanced NSCLC, have raised hopes that targeting other
deregulated growth factor signaling, such as the hepatocyte
growth factor (HGF)/MET pathway, will lead to new thera-
peutic options for NSCLC. Some studies showed the feasi-
bility to selectively target MET with ATP competitive small
molecule inhibitors and may provide a novel therapeutic
approach to lung cancer.7 Furthermore, interaction between
HGF/MET and EGFR signaling pathways have been recently
suggested.8 In addition, a recent study showed that MET am-
plification leads to gefinitib secondary resistance and could be an
explanation for this resistance in some patients.9 Thus, patients
with MET amplification could benefit from MET inhibitors,
alone or in association with irreversible EGFR inhibitors in
the case of an EGFR resistance T790M associated mutation.
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To our knowledge, no data are available for MET gene status
and primary EGFR-TKIs resistance in NSCLC.
TheMET gene is located on chromosome 7, band 7q31,
and encodes a transmembrane tyrosine kinase receptor for
HGF/SF (scatter factor) also located on chromosome 7, band
7q25. Binding of HGF/SF to MET induces receptor dimer-
ization and transphosphorylation, triggering conformational
changes that activate MET tyrosine kinase activity. This leads
to the activation of a number of signaling pathways, including
phosphoinositide-3-kinase, Ras-Rac/Rho, Ras-mitogen-acti-
vated protein kinase, and phospholipase C- pathways.10 In
addition to proliferative and antiapoptotic activities that are
common to many growth factors, MET elicits unique mo-
togenic and morphogenic effects by stimulating cell-cell
detachment, migration, invasiveness, tubule formation, and
branching.10,11 HGF is mainly expressed in primitive lung
mesenchyme and MET in primitive lung epithelium. HGF
appeared to modulate the phenotype of human bronchial
epithelial cells.12
These activities of MET signaling pathway provided
examples of the mechanisms by which this pathway is in-
volved in tumor development and progression. MET is usu-
ally considered as an oncogene.13 It has been implicated in
the progression of several human cancers such as pancreatic,
breast, gastric, esophageal cancers, and mesothelioma, neuro-
endocrine carcinoma of the lung and NSCLC.8,14–21 MET
appeared to be implicated especially in ADC. Cigarette
smoking induces overexpression of HGF in type II alveolar
pneumocytes and lung cancer cells.22 Overexpression of
HGF in lung cancer cells induces alveolar differentiation/
proliferation and MET activation may play special roles in
well differentiated lung ADC.20,23,24 Furthermore, HGF seemed
to have a particular role in BAC subtype of pulmonary ADC in
which high levels of HGF in bronchoalveolar lavage fluid is
associated with poorer outcome and was an independent prog-
nostic factor.25,26
If MET amplification has been already described in
gastric and esophageal cancers,15,16 few data are available
about MET copy number in NSCLC. The aim of our study
was to analyze simultaneously in a chemotherapy/TKI naive
NSCLC cohort, MET, EGFR, and K-Ras status to better
understanding the potential role of MET signaling pathway in
lung cancer.
PATIENTS AND METHODS
Patients and Tumor Specimens
Anonymized frozen samples from 106 NSCLC patients
surgically treated from 1999 to 2004 were obtained from the
Biologic Resource Center of the University Hospital of Stras-
bourg, in protocols approved by the institutional review
board. Stage was defined as recommended.27 All patients are
chemo and TKI naive at the time of surgery. All the patients
are non-Asian. The patients included 84 men and 22 women,
ranging in age from 41 to 80 years (average, 61 years). Only
seven (7%) of the patients were never smoker. The observa-
tion period ranged from 1 to 82 months, with a median
follow-up of 26 months. Patient characteristics are summa-
rized in Table 1.
Tumor and paired normal lung peripheral tissue sam-
ples obtained at the time of surgery were immediately stored
at 80°C. Tumors were histologically classified according to
the World Health Organization guidelines.2 Samples were
scored for differentiation (Table 1). Hematoxylin and eosin-
stained sections of frozen tissues were review by a patholo-
gist to identify region of tissue comprising at least 50% of
tumor cells.
DNA Extraction
Genomic DNA was isolated using conventional tech-
niques with QIAamp DNA kit (Qiagen, Courtaboeuf, France).
Normal and paired tumor DNA were amplified by fluorescent
polymerase chain reaction (PCR) for microsatellite (MS)
analysis with 48 markers distributed among the genome (3p,
4p, 5q, 6q, 7p, 7q, 8p, 9p, 9q, 11q, 13q, 14q, 15q, 17p, 17q,
and 20q). All cases included in this study presented allelic
imbalance (AI) at least at 50% confirming anatomo-patho-
logic features and presence of tumor cells. The nucleotide
sequences of primers used for MS analysis are available
through the Genome database (www.ncbi.nlm.gov/genome/
sts). Detailed MS and PCR conditions are available on re-
quest. For 7q31 (MET as candidate gene) and 7q25 (HGF as
candidate gene), four MS were chosen flanking each of
these genes, and six MS were chosen for 7p12 (EGFR as
candidate gene). All these MS were chosen the closest as
possible to the gene of interest.
Quantitative Relative Real-Time PCR
EGFR and MET copy number was determined by
quantitative real-time PCR using the LightCycler PCR 1.2
TABLE 1. Clinical and Pathological Features of 106 NSCLC
Patients with NSCLC, Classified by Histological Subtypes
All NSCLC ADC/BAC SCC
All 106 49a 57
Age, yr: mean (SD) 61 (10) 60 (10) 62 (10)
Gender
Men 84 (79%) 31 (63%) 53 (93%)
Women 22 (21%) 18 (37%) 4 (7%)
Current/former smoker 97 (91%) 40 (82%) 57 (100%)
Never-smoker 7 (7%) 7 (14%) 0 (0%)
Histologic differentiation
Well/moderate 74 (70%) 28 (57%) 46 (81%)
Poor 32 (30%) 21 (43%) 11 (19%)
Stage pTNM
I–IIIA 92 (87%) 40 (82%) 52 (91%)
IIIB–IVb 14 (13%) 9 (18%) 5 (9%)
Lung cancer relapse
Yes 51 (48%) 28 (57%) 23 (40%)
No 54 (51%) 20 (41%) 34 (59%)
Lung cancer death
Yes 52 (49%) 27 (55%) 32 (56%)
No 53 (50%) 21 (43%) 25 (44%)
a Of whom eight BAC features.
b Seven stages IV with unique metastasis.
NSCLC, non-small cell lung cancer; ADC, adenocarcinoma; BAC, bronchioloal-
veolar carcinoma; SCC, squamous cell carcinoma; SD, standard deviation.
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system (Roche Molecular Biochemicals, Mannheim, Ger-
many) and the LightCycler FastStart DNA Master SYBR
Green I Kit (Roche Diagnostics, Mannheim, Germany). Two
reference genes were used for each targeted gene: -globine
(11p15) and GADPH (12p13) for MET quantification; -glo-
bine (11p15) and COG-5 (7q22-31) for EGFR quantification.
The MET primers are directed at exon 15/intron 15 of MET.
The EGFR primers are directed at exon19/intron 18. Se-
quences of MET, -globine, and GAPDH PCR primers are
available on request. The EGFR and COG5 PCR primers are
previously described.28
The standard curve method was used to determine
targeted gene copy number relative to an endogenous refer-
ence gene and quantification was based on standard curves
established from serial dilutions of normal human genomic
DNA. Results are expressed as a normalized ratio calculated
using a calibrator sample consisting of a pool of normal
DNAs extracted from blood of noncancer patients. All cal-
culations were performed using the RelQuant software ver-
sion 1.01 (Roche Diagnostics, Mannheim, Germany). The
cut-off value of the normalized ratio was established for each
pair of reference/target genes (-globine and GAPDH for
MET; -globine and COG-5 for EGFR): after quantitative
real-time PCR of 30 normal lung DNA samples, an interval
for the normalized ratio values was calculated corresponding
to the mean (M)  2 standard deviations (SD). A lung tumor
sample was considered as amplified if its normalized ratio is
over M  2 SD. A lung tumor sample was considered as
deleted if its normalized ratio is under M  2 SD.
All specimens were analyzed in duplicate within each
paired test (targeted gene/reference gene) and this analysis
was twice realized.
Mutational Analysis
K-Ras mutation analysis was performed by real-time
PCR using LightCycler FastStart DNA Master Hyb Probe Kit
(Roche Diagnostics, Mannheim, Germany). Fluorescence
data obtained were analyzed using the LightCycler software
(Roche Diagnostics, Mannheim, Germany). Primers and con-
ditions of PCR are available on request. When a K-Ras
mutation is present, K-Ras sequencing is realized to precise
the type of mutation. The mutational analysis of exon 1
(codon 12,13) of K-Ras was performing using primers and
conditions previously reported.29 Purified DNA was se-
quenced using ABI BigDye Terminator kit v3.1 (ABI, Foster
City) on an ABI3100 genetic analyzer in both sens and
antisens directions from at least two independent amplifica-
tion products.
Statistical Analysis
Statistical analysis using 2 methods with exact p
values was used to compare qualitative data. Where appro-
priate, continuous variables were categorized before analysis.
The date of point was June 30, 2007. The Kaplan-Meier
method was used to estimate the probability of event-free
survival (EFS) and the log-rank test to detect difference in
survival curves. Cox’s proportional hazard models were used
to determine the impact of patient characteristics on EFS. All
statistical calculations were performed with the Statistical
Package for the Social science (SPSS) (number 15.0) statis-
tical software.
RESULTS
MET Copy Number in a TKI Naive NSCLC
Cohort
As little information is available in NSCLC about
tyrosine-kinase receptor gene status other than EGFR, we
analyzed MET at the DNA level in a chemo/TKI naive lung
cancer cohort. The 106 NSCLC of our collection were con-
sidered adequate for QPCR analysis when both pathology
review and MS analysis (48 markers) indicated the presence
of at least 50% of tumor cells. We used two sets of reference
genes at chromosomal regions 11p15 and 12p13, which
appeared less altered from CGH analysis of NSCLC co-
horts.30–32 We found that 31 (29%) of the patients presented
abnormal MET copy number. Among them, 22 patients
(21%) had MET amplification and nine patients (8%) had
MET deletion (Table 2). Allelotyping allowed us to reveal the
presence of alteration at a chromosome locus but does not
indicates whether it involves a deletion or an amplification of
this locus. Among the 22 MET amplified patients, 20 pre-
sented AI at 7q31 (MET candidate gene) and 15 also pre-
sented AI in a more centromeric region of the long arm of
chromosome 7, at 7q25 (HGF candidate gene). A CGH
microarray analysis (Agilent Technologies, Germany) was
performed in one amplified case and confirmed this amplifi-
cation (data not shown). Among the nine MET deleted pa-
tients, all nine presented AI at 7q31 and seven also presented
AI at 7q25. A CGH microarray analysis (Agilent Technolo-
gies, Germany) was performed in one deleted case and
confirmed this deletion (data not shown).
EGFR Copy Number/Mutation in a TKI Naive
NSCLC Cohort
As MET activates common or different signaling path-
ways to those involved in EGFR signaling, we study EGFR
gene status in the same NSCLC cohort previously analyzed
for MET. We found that 31 patients (29%) had an EGFR
amplification (Table 2). Any patient presented an EGFR
deletion. Among the 31 EGFR amplified patients, 24 pre-
sented AI at 7p12 (EGFR candidate gene).
K-Ras Mutations and MET/EGFR Status in a TKI
Naive NSCLC Cohort
Since K-Ras mutations are related to NSCLC, particu-
larly in ADC, males and current/former smokers, but are also
associated with EGFR-TKI primary resistance and appeared
exclusive with EGFR mutation, the 106 tumors have been
analyzed for exon 2 K-Ras mutation. Among all the patients,
11 (10.5%) presented K-Ras mutation (data not shown). All
these mutations were confirmed by direct sequencing. K-Ras
mutated patients represented four SCC and seven ADC/BAC,
in eight men and three women. All the K-Ras mutated
patients are current/former smokers (data not shown). Re-
markably, any MET amplified or deleted tumor presented
simultaneous K-Ras mutation (Table 2). None of the EGFR
amplified tumor presented simultaneous K-Ras mutation.
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TABLE 2. Biological Characteristics of 106 NSCLC Patients with NSCLC, Classified by Histological Subtypes
Patient Number MET Gene Copy Number Age, yr Gender Histology Smoking Status K-Ras Mutation EGFR Gene Copy Number
Biological characteristics of the SCC patients (n  57)
9 Amplified 69 W SCC Yes No Amplified
16 Amplified 80 M SCC Yes No Normal
18 Amplified 74 M SCC Yes No Normal
20 Amplified 45 M SCC Yes No Normal
43 Amplified 51 M SCC Yes No Amplified
65 Amplified 64 M SCC Yes No Normal
67 Amplified 52 M SCC Yes No Amplified
78 Amplified 60 M SCC Yes No Normal
88 Amplified 52 M SCC Yes No Amplified
105 Amplified 68 M SCC Yes No Normal
106 Amplified 62 M SCC Yes No Amplified
1115 Amplified 73 M SCC Yes No Amplified
9915 Normal 60 M SCC Yes Yes Normal
9925 Normal 65 M SCC Yes No Amplified
2 Normal 65 M SCC Yes No Normal
4 Normal 62 M SCC Yes No Normal
8 Normal 73 M SCC Yes No Normal
10 Normal 65 M SCC Yes No Normal
15 Normal 41 M SCC Yes No Normal
17 Normal 61 M SCC Yes No Normal
19 Normal 56 M SCC Yes No Normal
35 Normal 75 M SCC Yes No Normal
45 Normal 64 M SCC Yes No Normal
46 Normal 69 M SCC Yes No Normal
49 Normal 49 M SCC Yes No Normal
50 Normal 54 M SCC Yes Yes Normal
57 Normal 51 M SCC Yes No Normal
58 Normal 60 M SCC Yes No Amplified
60 Normal 60 M SCC Yes No Normal
61 Normal 49 M SCC Yes No Amplified
69 Normal 64 M SCC Yes No Normal
74 Normal 76 M SCC Yes No Normal
82 Normal 52 M SCC Yes No Amplified
83 Normal 75 M SCC Yes No Normal
86 Normal 74 W SCC Yes No Normal
89 Normal 71 M SCC Yes No Normal
90 Normal 48 M SCC Yes No Normal
92 Normal 70 M SCC Yes No Normal
100 Normal 43 M SCC Yes No Normal
111 Normal 61 M SCC Yes No Normal
112 Normal 63 W SCC Yes No Normal
118 Normal 68 M SCC Yes Yes Normal
119 Normal 66 M SCC Yes No Normal
120 Normal 41 W SCC Yes No Normal
1105 Normal 63 M SCC Yes No Amplified
1107 Normal 79 M SCC Yes No Amplified
1111 Normal 66 M SCC Yes Yes Normal
1114 Normal 77 M SCC Yes No Amplified
1127 Normal 52 M SCC Yes No Normal
1131 Normal 50 M SCC Yes No Amplified
994 Deleted 67 M SCC Yes No Amplified
1 Deleted 71 M SCC Yes No Normal
36 Deleted 55 M SCC Yes No Normal
59 Deleted 65 M SCC Yes No Amplified
(Continued)
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TABLE 2. (Continued )
Patient Number MET Gene Copy Number Age, yr Gender Histology Smoking Status K-Ras Mutation EGFR Gene Copy Number
93 Deleted 55 M SCC Yes No Amplified
98 Deleted 53 M SCC Yes No Normal
1119 Deleted 73 M SCC Yes No Amplified
Biological characteristics of ADC/BAC patients (n  49)
9951 Amplified 53 M ADC Yes No Normal
9986 Amplified 66 M ADC Yes No Normal
47 Amplified 68 W ADC Yes No Normal
76 Amplified 70 M ADC Yes No Amplified
80 Amplified 64 W ADC No No Normal
115 Amplified 50 M ADC Yes No Normal
1108 Amplified 52 M ADC Yes No Normal
1135 Amplified 74 W ADC Yes No Normal
48 Amplified 70 M ADC/BAC No No Amplified
1121 Amplified 49 W ADC/BAC Yes No Amplified
992 Normal 59 M ADC Yes No Amplified
9932 Normal 43 M ADC Yes No Normal
3 Normal 77 W ADC Yes No Amplified
6 Normal 76 W ADC Yes No Normal
7 Normal 51 M ADC Yes Yes Normal
14 Normal 62 M ADC Yes No Normal
21 Normal 59 W ADC Yes No Normal
23 Normal 62 W ADC No No Normal
32 Normal 52 M ADC No Normal
44 Normal 68 M ADC Yes No Normal
51 Normal 61 W ADC No No Amplified
52 Normal 44 M ADC Yes Yes Normal
53 Normal 73 M ADC Yes No Normal
63 Normal 44 W ADC Yes Yes Normal
64 Normal 44 M ADC Yes No Amplified
68 Normal 54 W ADC Yes No Normal
77 Normal 51 M ADC Yes Yes Normal
81 Normal 72 M ADC Yes No Amplified
104 Normal 61 M ADC Yes No Normal
107 Normal 79 M ADC Yes No Normal
108 Normal 52 W ADC Yes Yes Normal
109 Normal 67 M ADC Yes No Amplified
123 Normal 58 W ADC Yes No Normal
1101 Normal 50 M ADC Yes No Normal
1104 Normal 70 M ADC Yes Yes Normal
1106 Normal 70 M ADC No No Amplified
1109 Normal 60 M ADC Yes Yes Normal
1110 Normal 71 M ADC Yes No Normal
1112 Normal 62 M ADC Yes No Amplified
1116 Normal 55 M ADC Yes No Amplified
1118 Normal 53 W ADC Yes No Normal
1124 Normal 44 W ADC Yes Yes Normal
1125 Normal 65 W ADC No No Amplified
1128 Normal 67 M ADC Yes No Normal
1129 Normal 67 M ADC Yes No Normal
1130 Normal 55 W ADC No No Amplified
1133 Normal 50 M ADC Yes No Amplified
9938 Deleted 67 W ADC Yes No Normal
79 Deleted 76 M ADC Yes No Amplified
M, men; W, women; SCC, squamous cell carcinoma; ADC, adenocarcinoma; BAC, bronchioloalveolar carcinoma; smoking status: yes for current/former smoker; no for
never-smoker.
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MET and EGFR Status
As amplification of MET was recently implicated in
resistance to EGFR-TKI, we compared MET and EGFR gene
status in our surgically treated cohort of NSCLC. Among the
21 MET amplified patients, which could be analyzed for
EGFR gene quantification, nine (43%) patients are also am-
plified for EGFR. A patient presenting an EGFR amplifica-
tion with MET amplification was confirmed by microarray
analysis (data not shown). Thus, coamplification of MET and
EGFR is not so rare in NSCLC (9 of 106, 8.5%).
Clinical/Pathologic Correlates of MET
Amplification
Tyrosine kinase receptor EGFR pathway have been
extensively studied in NSCLC since gefitinib and erlotinib
have been used in NSCLC, with clinical response more
commonly observed in ADC/BAC histology, arising in non-
smokers, women, and patients of East Asian ethnicity.3 These
clinical features are well correlated with presence of EGFR
mutation but not EGFR amplification.28 In our study, there
was no correlation between the classic EGFR TKI-responsive
demographic groups and cases with MET amplification. The
frequency of MET amplification was 10 of 49 (20%) in
ADC/BAC and 12 of 57 (21%) in SCC; 2 of 7 (29%) in
nonsmokers and 20 of 97 (21%) in smokers; 5 of 22 (23%)
in women and 17 of 84 (20%) in men. There was no
difference of the prevalence of MET amplification among
age. There was also no difference of the prevalence of MET
amplification and the degree of tumor differentiation. Inter-
estingly, MET amplification and EGFR amplification were
marginally correlated in SCC (p  0.06) but are independent
events in ADC/BAC.
In the whole population, EFS was trend to be shorter in
MET amplified patients (median EFS, 38 versus 51 months;
HR, 1.32; 95% CI, 0.99–2.53) (Figure 1). This trend is found
again only in ADC/BAC (median EFS, 14 versus 42 months;
HR, 1.91; 95% CI, 0.58–4.27, p  0.09) but not in the
histologic subgroup of SCC (HR, 0.83; 95% CI, 0.27–2.54)
(Figure 1). In the whole group, EGFR amplification is not a
prognosis factor (Figure 2). In the histologic subgroup of
ADC/BAC, EFS was trend to be shorter in EGFR amplified
patients (median EFS, 10 versus 42 months; HR, 2.05; 95%
CI, 0.90–4.76, p  0.07) and not in the histologic subgroup
of SCC (HR, 0.84; 95% CI, 0.33–2.16) (Figure 2). Alto-
gether, these results suggest that MET and EGFR amplifica-
tions could have different functions in NSCLC carcinogene-
sis among NSCLC histologic subtypes.
Clinical Correlates of MET Deletion
In contrast to EGFR localized in the same chromosome
7, which is never deleted,MET could be deleted in nine of our
106 NSCLC (8%) which is at lower extent than MET ampli-
fication frequency. MET was deleted in 2 of 49 (4%) in
ADC/BAC and in 7 of 57 (12%) in SCC; in 9 of 97 (9%) in
smokers and none of the seven nonsmokers; in 1 of the 22
(4%) women and 8 of 84 (9%) in men. MET deletion is not
a prognostic factor (data not shown). Thus, MET appeared to
be also deleted in NSCLC, particularly in SCC, but less
frequently compared with MET amplification.
DISCUSSION
Tyrosine-kinase receptors have recently been impli-
cated in lung carcinogenesis, at first EGFR, located at 7p12.
Another tyrosine-kinase receptor, MET, located at the same
chromosome at 7q31, was recently identified to have also
importance in NSCLC. Even trisomies of chromosome 7
have been described in lung cancers,32 very few data about
MET status are actually available in NSCLC. We report here
the results of MET gene copy number in a EGFR-TKI naive
NSCLC population. In this work, we identified a subgroup
FIGURE 1. Kaplan-Meier curves for event-free survival
(months) stratified according to MET copy number (A, B, C).
A, B, and C represent the whole NSCLC (n  106), the ADC/
BAC (n  49), and the SCC (n  57) populations, respec-
tively. NSCLC, non-small cell lung cancer; SCC, squamous
cell carcinoma; ADC, adenocarcinoma; BAC, bronchioloal-
veolar carcinoma.
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with MET amplification (21%) and a subgroup with EGFR
amplification (32%), with a few cases of coamplification of
MET and EGFR genes (8.5%).
One of the common oncogenic pathways activated by
MET and EGFR is Ras-mitogen-activated protein kinase. In
our cohort, K-Rasmutations was associated neither withMET
amplified not EGFR amplified cases. These results are in
agreement with previous results, showing that K-Ras muta-
tions were not associated with EGFR and MET muta-
tions.19,28,29,33–36 It was recently demonstrated that K-Ras
alleles were wild type in MET amplified lung cancer cell
lines, with K-Ras activated similarly to the homozygous
mutant K-Ras in lung cancer cells.37 Conversely, MET am-
plification could be an alternative mechanism for EGFR-TKI
primary resistance, which was already described for K-Ras
mutated lung tumors.38
Elevated MET copy number is not so rare since 22
patients (21%) are amplified in our cohort. In fact, MET/HGF
signaling pathways occur in lung cancer in a paracrine man-
ner with carcinoma cells expressing MET and stroma cells
expressing HGF.10 In MET amplified ADC lung cancer cell
lines, MET receptors were constitutively overexpressed and
phosphorylated with a ligand-independent manner. In lung
cancer cell lines with lower levels of MET, MET appeared to
be phosphorylated only on addition of the ligand HGF.37 In
this latter work, ERK signaling pathway is activated at a
lower level in MET amplified cell lines than in HGF stimu-
lated non-MET amplified lines. Thus, the signaling activation
by MET kinase seemed to depend on the MET copy number
and/or the HGF levels. For example, phosphoinositide-3-
kinase (PI3K) pathway could be preferentially activated in
MET amplified lung tumors, with more cell survival.10
Among the 21 MET amplified cases, nine are also
amplified for EGFR. In fact, the results of quantitative real-
time PCR (for EGFR located at 7p12 and MET located at
7q31) could be linked to an isolated amplification of the
target gene, or to the presence of an amplicon from 7q31 to
7p12, or to a trisomy of chromosome 7 (associated or not
with a targeted gene amplification). In our cohort, eight of the
nine patients amplified for both EGFR and MET, had also AI
at 7q25 (one patient is homozygous at this locus), suggesting
the presence of an amplicon or a trisomy of chromosome 7
for these patients.
It has been described that not all the patients presenting
activating EGFR mutation respond to EGFR-TKIs.28,29,34,35
Another molecular alteration than K-Ras mutation should be
responsible of this primary TKIs-EGFR resistance.38,39 Our
results suggest a possible explanation for primary EGFR TKI
no change or stability, depending on the relative importance
of MET and EGFR pathways in a lung tumor. Secondary
EGFR-TKI resistance have been related to EGFR exon 20
T790M and more recently to another EGFR exon 19 mutation
D761Y.38,40 In a recent publication,9 secondary gefitinib re-
sistance in NSCLC has been related to EGFR T790M muta-
tion and/or MET amplification, analyzed by QPCR or by
fluorescence in situ hybridization in the samples of gefitinib-
resistance tumors. They did not find MET amplification in
pregefitinib treatment tumors but all the tumors have been
selected to correspond to initially gefitinib sensible patients.
Thus, it could be possible that beside EGFR mutation, rela-
tive importance of each MET/EGFR amplification could play
a role in response to EGFR-TKIs, in primary or in secondary
resistance.9
MET amplification seems to play different roles among
NSCLC histologic subtypes. Patients with relatively distinct
clinical (never smokers, East Asians ethnicity, females),
pathologic (ADC), and molecular (activating mutations of the
tyrosine kinase domain of EGFR) features demonstrated
FIGURE 2. Kaplan-Meier curves for event-free survival
(months) stratified according to EGFR copy number (A, B,
C). A, B, and C represent the whole NSCLC (n  106), the
ADC/BAC (n  49), and the SCC (n  57) populations, re-
spectively. NSCLC, non-small cell lung cancer; SCC, squa-
mous cell carcinoma; ADC, adenocarcinoma; BAC, bronchi-
oloalveolar carcinoma.
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response to targeted EGFR-TKIs.28,29,34–36 As previously
found for EGFR amplification, MET amplification frequency
is indistinguishable on our cohort from the majority of
NSCLC. In contrast to EGFR amplification,28 no correlation
was found between MET amplification and age.
After different expression ofMET among histologic NSCLC
subtypes, some studies assessed more aggressive behavior in
MET/HGF immunohistological positive ADC.19–21,39,41 MET
overexpression was detected in all cases of ADC with am-
plification of the MET gene detected by an array-based
comparative genomic hybridization analysis (24%, 13 of
55).39 Some differences between histologic subtypes were
also described in an immunohistochemical study analyzing
functional activity of MET in terms of expression of
phospho-MET: none SCC was detected with phospho-MET
(Y1230/1234/1235) compared with ADC, and this result was
confirmed by Affymetrix microarray.19 In fact, survival anal-
ysis of our cohort give different values of MET amplification
by histologic subtypes of NSCLC. MET amplification
showed a trend toward poor prognosis in ADC, suggesting
that anti-MET could be an alternative therapeutic in these
histologic NSCLC subtype, particularly for EGFR-TKI resis-
tant tumors. In contrast, MET amplification is not a prognosis
factor in SCC. Besides its classic oncogenic role, HGF
overexpression could inhibit carcinoma cell proliferation,
such as hepatocellular carcinoma or lung SCC.23,42 MET
amplification is correlated with EGFR amplification only in
our SCC population, and appeared independent events in
ADC. Altogether, the balance between MET and EGFR
pathway seems to have different role depending on the different
histologic subtypes, and particularly in ADC.
Nevertheless, these results should be confirmed in more
important chimio/EGFR-TKI naive cohorts, as well as in
chimiotherapy and/or EGFR-TKI treated patients and be
compared with immunohistochemical analysis (phospho-MET)
and HGF status.
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